U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H37NO4
Molecular Weight 415.5665
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SALMETEROL

SMILES

C(CCCOCCCCc1ccccc1)CCNCC(c2ccc(c(c2)CO)O)O

InChI

InChIKey=GIIZNNXWQWCKIB-UHFFFAOYSA-N
InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/mtm/salmeterol-inhalation.html http://www.rxlist.com/serevent-diskus-drug.htm http://www.wikidoc.org/index.php/Salmeterol

Salmeterol is a long-acting beta2-adrenergic agonist. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these is not yet established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects. It is FDA approved for the treatment of asthma, prevention of exercise-induced bronchospasm, maintenance treatment of chronic obstructive pulmonary disease. Common adverse reactions include musculoskeletal pain, headache, influenza, nasal/sinus congestion, pharyngitis, rhinitis, tracheitis/bronchitis, cough, throat irritation, viral respiratory infection. Salmeterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of salmeterol on the vascular system may be potentiated by these agents. Coadministration of salmeterol and ketoconazole was associated with more frequent increases in QTc duration compared with salmeterol and placebo administration.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in rat. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.5 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SEREVENT

Approved Use

ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1)

Launch Date

7.6031997E11
Palliative
SEREVENT

Approved Use

ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1)

Launch Date

7.6031997E11
Preventing
SEREVENT

Approved Use

ADVAIR DISKUS is a combination product containing a corticosteroid and a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.2) 1.1 Treatment of Asthma ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1)

Launch Date

7.6031997E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
319 pg/mL
50 μg single, oral
dose: 50 μg
route of administration: Oral
experiment type: SINGLE
co-administered: FLUTICASONE PROPIONATE
SALMETEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
167 pg/mL
50 μg 2 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SALMETEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
464 pg × h/mL
50 μg single, oral
dose: 50 μg
route of administration: Oral
experiment type: SINGLE
co-administered: FLUTICASONE PROPIONATE
SALMETEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.72 h
50 μg single, oral
dose: 50 μg
route of administration: Oral
experiment type: SINGLE
co-administered: FLUTICASONE PROPIONATE
SALMETEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.5 h
50 μg 2 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SALMETEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
50 μg 2 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SALMETEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
n = 31
Health Status: unhealthy
Condition: asthma
Age Group: 30
Sex: M+F
Population Size: 31
Sources:
Other AEs: Headache, Dizziness...
Other AEs:
Headache (5 patients)
Dizziness (2 patients)
Tremor (5 patients)
Palpitations (1 patient)
Muscle cramps (1 patient)
Sources:
400 ug single, respiratory
Dose: 400 ug
Route: respiratory
Route: single
Dose: 400 ug
Sources:
healthy, 34.3
n = 10
Health Status: healthy
Age Group: 34.3
Sex: M
Population Size: 10
Sources:
Other AEs: Headache, Tremor...
Other AEs:
Headache (5 patients)
Tremor (5 patients)
Palpitations (3 patients)
Sources:
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
n = 211
Health Status: unhealthy
Condition: asthma
Age Group: 4-11
Population Size: 211
Sources:
Other AEs: Ear disorder, Pharyngitis...
Other AEs:
Ear disorder (4%)
Pharyngitis (6%)
Headache (17%)
Asthma (4%)
Skin rash (4%)
Urticaria (3%)
Sources:
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
n = 149
Health Status: unhealthy
Condition: asthma
Age Group: >12
Population Size: 149
Sources:
Other AEs: Nasal sinus congestion, Rhinitis...
Other AEs:
Nasal sinus congestion (9%)
Rhinitis (5%)
Headache (13%)
Asthma (3%)
Tracheobronchitis (7%)
Influenza (5%)
Sources:
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Other AEs: Hypertension, Throat irritation...
Other AEs:
Hypertension (4%)
Throat irritation (7%)
Congestion nasal (4%)
Sinusitis (4%)
Ear disorder (3%)
Nausea and vomiting (3%)
Cough (5%)
Rhinitis (4%)
Respiratory tract infection viral (5%)
Musculoskeletal pain (12%)
Muscle cramps (3%)
Headache (14%)
Dizziness (4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Muscle cramps 1 patient
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
n = 31
Health Status: unhealthy
Condition: asthma
Age Group: 30
Sex: M+F
Population Size: 31
Sources:
Palpitations 1 patient
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
n = 31
Health Status: unhealthy
Condition: asthma
Age Group: 30
Sex: M+F
Population Size: 31
Sources:
Dizziness 2 patients
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
n = 31
Health Status: unhealthy
Condition: asthma
Age Group: 30
Sex: M+F
Population Size: 31
Sources:
Headache 5 patients
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
n = 31
Health Status: unhealthy
Condition: asthma
Age Group: 30
Sex: M+F
Population Size: 31
Sources:
Tremor 5 patients
84 ug 2 times / day multiple, respiratory
Dose: 84 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 84 ug, 2 times / day
Sources:
unhealthy, 30
n = 31
Health Status: unhealthy
Condition: asthma
Age Group: 30
Sex: M+F
Population Size: 31
Sources:
Palpitations 3 patients
400 ug single, respiratory
Dose: 400 ug
Route: respiratory
Route: single
Dose: 400 ug
Sources:
healthy, 34.3
n = 10
Health Status: healthy
Age Group: 34.3
Sex: M
Population Size: 10
Sources:
Headache 5 patients
400 ug single, respiratory
Dose: 400 ug
Route: respiratory
Route: single
Dose: 400 ug
Sources:
healthy, 34.3
n = 10
Health Status: healthy
Age Group: 34.3
Sex: M
Population Size: 10
Sources:
Tremor 5 patients
400 ug single, respiratory
Dose: 400 ug
Route: respiratory
Route: single
Dose: 400 ug
Sources:
healthy, 34.3
n = 10
Health Status: healthy
Age Group: 34.3
Sex: M
Population Size: 10
Sources:
Headache 17%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
n = 211
Health Status: unhealthy
Condition: asthma
Age Group: 4-11
Population Size: 211
Sources:
Urticaria 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
n = 211
Health Status: unhealthy
Condition: asthma
Age Group: 4-11
Population Size: 211
Sources:
Asthma 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
n = 211
Health Status: unhealthy
Condition: asthma
Age Group: 4-11
Population Size: 211
Sources:
Ear disorder 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
n = 211
Health Status: unhealthy
Condition: asthma
Age Group: 4-11
Population Size: 211
Sources:
Skin rash 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
n = 211
Health Status: unhealthy
Condition: asthma
Age Group: 4-11
Population Size: 211
Sources:
Pharyngitis 6%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, 4-11
n = 211
Health Status: unhealthy
Condition: asthma
Age Group: 4-11
Population Size: 211
Sources:
Headache 13%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
n = 149
Health Status: unhealthy
Condition: asthma
Age Group: >12
Population Size: 149
Sources:
Asthma 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
n = 149
Health Status: unhealthy
Condition: asthma
Age Group: >12
Population Size: 149
Sources:
Influenza 5%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
n = 149
Health Status: unhealthy
Condition: asthma
Age Group: >12
Population Size: 149
Sources:
Rhinitis 5%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
n = 149
Health Status: unhealthy
Condition: asthma
Age Group: >12
Population Size: 149
Sources:
Tracheobronchitis 7%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
n = 149
Health Status: unhealthy
Condition: asthma
Age Group: >12
Population Size: 149
Sources:
Nasal sinus congestion 9%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy, >12
n = 149
Health Status: unhealthy
Condition: asthma
Age Group: >12
Population Size: 149
Sources:
Musculoskeletal pain 12%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Headache 14%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Ear disorder 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Muscle cramps 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Nausea and vomiting 3%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Congestion nasal 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Dizziness 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Hypertension 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Rhinitis 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Sinusitis 4%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Cough 5%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Respiratory tract infection viral 5%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Throat irritation 7%
50 ug 2 times / day multiple, respiratory
Recommended
Dose: 50 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 50 ug, 2 times / day
Sources:
unhealthy
n = 341
Health Status: unhealthy
Condition: COPD
Population Size: 341
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
unlikely
yes
yes
yes
yes (co-administration study)
Comment: Coadministration of inhaled Salmetrol and oral ketoconazole (strong CYP3A4 inhibitor) for 7 days increased Salmetrol AUC by 16-fold and Cmax by 1.4-fold. Coadministration of Erythromycin (moderate CYP3A4 inhibitor) increased inhaled Salmeterol Cmax,ss by 40% (3.6-beat/min in heart rate, 5.8-msec increase in QTc interval).
Page: 13-14, 21-22
Tox targets
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease.
1991 Nov
Effects of salmeterol and terbutaline on IgE-mediated dermal reactions and inflammatory events in skin chambers in atopic patients.
1996 Sep
Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients.
1998 May-Jun
Potential masking effects of salmeterol on airway inflammation in asthma.
1998 Sep
Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma.
1999 Aug
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
1999 Jun
Asthma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics.
1999 Oct
Effects of a range of beta2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells.
1999 Oct
Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
2001
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma.
2002 Jul
Stimulation of beta 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a cAMP/protein kinase A-independent pathway.
2003 May 9
Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies.
2004 Jan
Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells.
2004 Jan
Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma.
2004 Nov
Heat-induced degradation of overexpressed glucocorticoid receptor Separate protective roles of hsp90 and hsp70.
2005 Feb
Examination of 209 drugs for inhibition of cytochrome P450 2C8.
2005 Jan
Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists.
2005 Jan 28
Agonist-specific activation of the beta2-adrenoceptor/Gs-protein and beta2-adrenoceptor/Gi-protein pathway in adult rat ventricular cardiomyocytes.
2006 Apr
Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.
2006 Jun 20
Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database.
2007
Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma.
2007 Feb 1
The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells.
2007 Nov
Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea.
2010 Apr
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
2010 Jul
Patents

Sample Use Guides

Asthma and Chronic Obstructive Pulmonary Disease: the usual dosage for adults and children 4 years of age and older is 1 inhalation (50 mcg) twice daily (morning and evening, approximately 12 hours apart). Exercise-Induced Bronchospasm: One inhalation of SEREVENT DISKUS at least 30 minutes before exercise.
Route of Administration: Respiratory
Since fibroblasts express beta2-adrenoreceptors, the effects of different concentrations (0.1-100 nM) of salmeterol on lung fibroblast proliferation and adhesion molecule expression were evaluated. A significant downregulation of ICAM-1 or H-CAM expression was demonstrated in the presence of Salmeterol, at all concentrations tested (0.1-100 nM; p<0.01).
Name Type Language
SALMETEROL
HSDB   INN   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
SALMETEROL [MI]
Common Name English
SALMETEROL [HSDB]
Common Name English
SALMETEROL [WHO-DD]
Common Name English
GR 33343 X
Code English
SALMETEROL [VANDF]
Common Name English
SN408D
Code English
SALMETEROL [INN]
Common Name English
SALMETEROL [USAN]
Common Name English
GR-33343-X
Code English
Classification Tree Code System Code
WHO-ATC R03AC12
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
NDF-RT N0000009922
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
WHO-VATC QR03AC12
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
WHO-VATC QR03AK06
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
EMA ASSESSMENT REPORTS LABAZENIT (REFUSED: ASTHMA)
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
WHO-ATC R03AK06
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
WHO-ATC R03AK12
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
NDF-RT N0000175779
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
LIVERTOX 869
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
NCI_THESAURUS C319
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
Code System Code Type Description
MESH
C057823
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
IUPHAR
559
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
NCI_THESAURUS
C29443
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
DRUG BANK
DB00938
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
EVMPD
SUB10430MIG
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
RXCUI
36117
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
SALMETEROL
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
FDA UNII
2I4BC502BT
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
DRUG CENTRAL
2419
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
CAS
89365-50-4
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
PUBCHEM
5152
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
LACTMED
Salmeterol
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
EPA CompTox
89365-50-4
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
INN
5578
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
ChEMBL
CHEMBL1263
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY
MERCK INDEX
M9745
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY Merck Index
HSDB
7315
Created by admin on Sat Jun 26 12:45:39 UTC 2021 , Edited by admin on Sat Jun 26 12:45:39 UTC 2021
PRIMARY